Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Acute Promyelocytic Leukemia | Research article

The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia

Authors: Zahra Mohammadzadeh, Azadeh Omidkhoda, Bahram Chahardouli, Ghazaleh Hoseinzadeh, Kamran Ali Moghaddam, Seyed Asadollah Mousavi, Shahrbano Rostami

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Although arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) are well-tolerated and effective treatments for Acute Promyelocytic Leukemia (APL), Differentiation Syndrome (DS) is a lethal side effect in some patients. The pathogenesis of DS is complex and not well understood; however, it is considered as an inflammatory response due to cytokines release of differentiated cells. Moreover, adhesion molecules that are widely expressed on the surface of differentiated cells and gene expression changes of transglutaminase2 (TGM2) are mechanisms involved in the development of DS. The purpose of this study was to assess the association of single nucleotide polymorphisms (SNP) of Intercellular Adhesion Molecule-1 (ICAM-1), chemokine (C-C motif) ligand 2 (CCL2) and TGM2 as inflammatory factors with differentiation syndrome susceptibility.

Methods

DNA was extracted from 133 APL patients and 100 normal controls. Assessment according to the PETHEMA criteria revealed that 13.5% of these patients experienced differentiation syndrome. Tetra-ARMS PCR and PCR-RFLP were done to amplify DNA fragments in APL patients with and without DS. Then DNA sequencing was done to validate the results. SNPStats, SPSS and Finch TV were used to analyze the results.

Results

A significant correlation was found between rs4811528 in the TGM2 gene and differentiation syndrome susceptibility (P = 0.002, 95% CI = 1.74–18.81, OR = 5.72) while rs5498 in ICAM-1, rs1024611 in CCL2, and rs7270785 in TGM2 genes showed no correlation with differentiation syndrome. The G allele of rs7270785 and rs4811528 showed a haplotypic association with differentiation syndrome (P = 0.03, 95% CI = 1.13–13.86, OR = 3.96).

Conclusions

AA genotype of the TGM2 SNP (rs4811528) may be a risk factor for development of DS in patients with APL following the use of ATRA/ATO.
Literature
1.
go back to reference Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–107.CrossRef Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–107.CrossRef
2.
go back to reference Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–15.CrossRef Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–15.CrossRef
3.
go back to reference Dore AI, Santana-Lemos BA, Coser VM, Santos FL, Dalmazzo LF, Lima AS, et al. The association of ICAM-1 exon 6 (E469K) but not of ICAM-1 exon 4 (G241R) and PECAM-1 exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. J Leukoc Biol. 2007;82(5):1340–3.CrossRef Dore AI, Santana-Lemos BA, Coser VM, Santos FL, Dalmazzo LF, Lima AS, et al. The association of ICAM-1 exon 6 (E469K) but not of ICAM-1 exon 4 (G241R) and PECAM-1 exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. J Leukoc Biol. 2007;82(5):1340–3.CrossRef
4.
go back to reference Luesink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009;114(27):5512–21.CrossRef Luesink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood. 2009;114(27):5512–21.CrossRef
5.
go back to reference Tsai WH, Shih CH, Lin CC, Ho CK, Hsu FC, Hsu HC. MCP-1 in the migration of differentiated leukemic cells toward alveolar epithelial cells. Eur Respir J. 2008;31(5):957–62. Tsai WH, Shih CH, Lin CC, Ho CK, Hsu FC, Hsu HC. MCP-1 in the migration of differentiated leukemic cells toward alveolar epithelial cells. Eur Respir J. 2008;31(5):957–62.
6.
go back to reference Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol. 2010;151(3):209–20.CrossRef Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol. 2010;151(3):209–20.CrossRef
7.
go back to reference Rego EM, Santana-Lemos BA, Tamarozzi MB. Differentiation syndrome in acute promyelocytic leukemia: pathogenesis and risk factors. Rev Bras Hematol Hemoter. 2008;30:33–6.CrossRef Rego EM, Santana-Lemos BA, Tamarozzi MB. Differentiation syndrome in acute promyelocytic leukemia: pathogenesis and risk factors. Rev Bras Hematol Hemoter. 2008;30:33–6.CrossRef
8.
go back to reference Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood J Am Soc Hematol. 2009;113(9):1875–91. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood J Am Soc Hematol. 2009;113(9):1875–91.
9.
go back to reference Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019. Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019.
10.
go back to reference Csomós K, Német I, Fésüs L, Balajthy Z. Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. Blood. 2010;116(19):3933–43. Csomós K, Német I, Fésüs L, Balajthy Z. Tissue transglutaminase contributes to the all-trans-retinoic acid-induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia. Blood. 2010;116(19):3933–43.
11.
go back to reference Rego EM, De Santis GC. Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. Med J Hematol Infect Dis. 2011;3(1):e2011048. Rego EM, De Santis GC. Differentiation syndrome in promyelocytic leukemia: clinical presentation, pathogenesis and treatment. Med J Hematol Infect Dis. 2011;3(1):e2011048.
12.
go back to reference Bradford M, Law MH, Stewart AD, Shaw DJ, Megson IL, Wei J. The TGM2 gene is associated with schizophrenia in a British population. Am J Med Genet B Neuropsychiatr Genet. 2009;150(3):335–40.CrossRef Bradford M, Law MH, Stewart AD, Shaw DJ, Megson IL, Wei J. The TGM2 gene is associated with schizophrenia in a British population. Am J Med Genet B Neuropsychiatr Genet. 2009;150(3):335–40.CrossRef
13.
go back to reference Zablotna M, Sobjanek M, Purzycka-Bohdan D, Szczerkowska-Dobosz A, Nedoszytko B, Nowicki R. The-2518 a/G MCP-1 and-403 G/a RANTES promoter gene polymorphisms are associated with psoriasis vulgaris. Clin Exp Dermatol. 2016;41(8):878–83.CrossRef Zablotna M, Sobjanek M, Purzycka-Bohdan D, Szczerkowska-Dobosz A, Nedoszytko B, Nowicki R. The-2518 a/G MCP-1 and-403 G/a RANTES promoter gene polymorphisms are associated with psoriasis vulgaris. Clin Exp Dermatol. 2016;41(8):878–83.CrossRef
14.
go back to reference Zhang X, Huang J, Bai J, Lu W, Zhang M, Mei H. Association of Polymorphisms in intercellular adhesion molecule 1 (ICAM-1) gene with Cancer susceptibility: a meta-analysis of 14 case-control studies. Med Sci Monit. 2016;22:569.CrossRef Zhang X, Huang J, Bai J, Lu W, Zhang M, Mei H. Association of Polymorphisms in intercellular adhesion molecule 1 (ICAM-1) gene with Cancer susceptibility: a meta-analysis of 14 case-control studies. Med Sci Monit. 2016;22:569.CrossRef
15.
go back to reference Cheng D, Liang B. Intercellular adhesion molecule-1 (ICAM-1) polymorphisms and cancer risk: a meta-analysis. Iran J Public Health. 2015;44(5):615.PubMedPubMedCentral Cheng D, Liang B. Intercellular adhesion molecule-1 (ICAM-1) polymorphisms and cancer risk: a meta-analysis. Iran J Public Health. 2015;44(5):615.PubMedPubMedCentral
16.
go back to reference Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29(6):313–26.CrossRef Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interf Cytokine Res. 2009;29(6):313–26.CrossRef
17.
go back to reference Bianchi N, Bianchi S, Bergamini CM. Spotlight on the transglutaminase 2 gene: a focus on genomic and transcriptional aspects. Biochem J. 2018:1643–67. Bianchi N, Bianchi S, Bergamini CM. Spotlight on the transglutaminase 2 gene: a focus on genomic and transcriptional aspects. Biochem J. 2018:1643–67.
18.
go back to reference Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 2009;89(3):991–1023.CrossRef Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 2009;89(3):991–1023.CrossRef
19.
go back to reference Cimino L, Boiardi L, Aldigeri R, Casali B, Nicoli D, Farnetti E, et al. G/R 241 polymorphism of intercellular adhesion molecule 1 (ICAM-1) is associated with Fuchs uveitis. Invest Ophthalmol Vis Sci. 2010;51(9):4447–50.CrossRef Cimino L, Boiardi L, Aldigeri R, Casali B, Nicoli D, Farnetti E, et al. G/R 241 polymorphism of intercellular adhesion molecule 1 (ICAM-1) is associated with Fuchs uveitis. Invest Ophthalmol Vis Sci. 2010;51(9):4447–50.CrossRef
20.
go back to reference Li H, Jin Z, Li X, Wu L, Jin J. Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. Clin Transl Oncol. 2017;19(8):1018–27.CrossRef Li H, Jin Z, Li X, Wu L, Jin J. Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. Clin Transl Oncol. 2017;19(8):1018–27.CrossRef
21.
go back to reference Sergi C, Kassam S, Meyer P, Corfield A. Single nucleotide polymorphisms (SNPs): history, biotechnological outlook and practical applications. Curr Pharmacogenom. 2005:3. Sergi C, Kassam S, Meyer P, Corfield A. Single nucleotide polymorphisms (SNPs): history, biotechnological outlook and practical applications. Curr Pharmacogenom. 2005:3.
22.
go back to reference Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–7.CrossRef Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–7.CrossRef
23.
go back to reference De Santis GC, de Barros Tamarozzi M, Sousa RB, Moreno SE, Secco D, Garcia AB, et al. Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica. 2007;92(12):1615–22. De Santis GC, de Barros Tamarozzi M, Sousa RB, Moreno SE, Secco D, Garcia AB, et al. Adhesion molecules and differentiation syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica. 2007;92(12):1615–22.
24.
go back to reference Luesink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood J Am Soc Hematol. 2009;114(27):5512–21. Luesink M, Pennings JL, Wissink WM, Linssen PC, Muus P, Pfundt R, et al. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood J Am Soc Hematol. 2009;114(27):5512–21.
25.
go back to reference Birendra K, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymp Myeloma Leuk. 2016;16(8):460–5.CrossRef Birendra K, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymp Myeloma Leuk. 2016;16(8):460–5.CrossRef
26.
go back to reference Umare VD, Pradhan VD, Rajadhyaksha AG, Ghosh K, Nadkarni AH. A functional SNP MCP-1 (− 2518A/G) predispose to renal disorder in Indian systemic lupus Erythematosus patients. Cytokine. 2017;96:189–94.CrossRef Umare VD, Pradhan VD, Rajadhyaksha AG, Ghosh K, Nadkarni AH. A functional SNP MCP-1 (− 2518A/G) predispose to renal disorder in Indian systemic lupus Erythematosus patients. Cytokine. 2017;96:189–94.CrossRef
27.
go back to reference Masselli E, Carubbi C, Cambò B, Pozzi G, Gobbi G, Mirandola P, et al. The-2518 a/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. Leukemia. 2018:1. Masselli E, Carubbi C, Cambò B, Pozzi G, Gobbi G, Mirandola P, et al. The-2518 a/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. Leukemia. 2018:1.
28.
go back to reference Sharma NK, Sharma K, Singh R, Sharma SK, Anand A. CCL2 single nucleotide polymorphism of rs1024611 implicates prominence of inflammatory cascade by univariate modeling in Indian AMD. PloS One. 2018;13(4):e0193423. Sharma NK, Sharma K, Singh R, Sharma SK, Anand A. CCL2 single nucleotide polymorphism of rs1024611 implicates prominence of inflammatory cascade by univariate modeling in Indian AMD. PloS One. 2018;13(4):e0193423.
29.
go back to reference Wang J, Liu Y, Wang Z, Du W, Hui L, Zhao X, et al. Lack of genetic association of the TGM2 gene with schizophrenia in a Chinese population. Psychiatr Genet. 2015;25(6):259–62.CrossRef Wang J, Liu Y, Wang Z, Du W, Hui L, Zhao X, et al. Lack of genetic association of the TGM2 gene with schizophrenia in a Chinese population. Psychiatr Genet. 2015;25(6):259–62.CrossRef
30.
go back to reference Jambrovics K, Uray IP, Keresztessy Z, Keillor JW, Fésüs L, Balajthy Z. Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation. Haematologica. 2019;104(3):505–15.CrossRef Jambrovics K, Uray IP, Keresztessy Z, Keillor JW, Fésüs L, Balajthy Z. Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation. Haematologica. 2019;104(3):505–15.CrossRef
Metadata
Title
The impact of ICAM-1, CCL2 and TGM2 gene polymorphisms on differentiation syndrome in acute promyelocytic leukemia
Authors
Zahra Mohammadzadeh
Azadeh Omidkhoda
Bahram Chahardouli
Ghazaleh Hoseinzadeh
Kamran Ali Moghaddam
Seyed Asadollah Mousavi
Shahrbano Rostami
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-07783-y

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine